Summary
The distinct topographic Hox expression patterns observed in vascular smooth muscle cells (VSMCs) of the adult cardiovascular system suggest that these transcriptional regulators are critical for maintaining region-specific physiological properties of blood vessels. To test this proposition, we expanded the vascular Hoxc11 expression domain normally restricted to the lower limbs by utilizing an innovative integrated tetracycline regulatory system and Transgelin promoter elements to induce Hoxc11 expression universally in VSMCs of transgenic mice. Ectopic Hoxc11 expression in carotid arteries, aortic arch and descending aorta resulted in drastic vessel wall remodeling involving elastic laminae fragmentation, medial smooth muscle cell loss, and intimal lesion formation. None of these alterations were observed upon induction of Hoxc11 transgene expression in the femoral artery, i.e. the natural Hoxc11 activity domain, although this vessel was greatly enlarged, comparable to the topographically restricted vascular changes seen in Hoxc11−/− mice. To begin defining Hoxc11-controlled pathways of vascular remodeling, we performed immunolabeling studies in conjunction with co-transfection and chromatin immunoprecipitation (ChIP) assays using mouse vascular smooth muscle (MOVAS) cells. The results suggest direct transcriptional control of two members of the matrix metalloproteinase (Mmp) family, including Mmp2 and Mmp9 that are known as key players in the inception and progression of vascular remodeling events. In summary, the severe vascular abnormalities resulting from the induced dysregulated expression of a Hox gene with regional vascular patterning functions suggest that proper Hox function and regulation is critical for maintaining vascular functional integrity.
Introduction
A VSMC fate map of the aorta and its main branches revealed that VSMCs originating from different sources (neural crest, secondary heart field, somites, mesangioblasts, proepicardium, splanchnic mesoderm, mesothelium) reside in distinct segments (Majesky, 2007). This inherent regional diversity may be viewed as superimposed on VSMC heterogeneity based on differentiation status during normal development, as well as phenotype modulation during vascular injury and disease (Gittenberger-de Groot et al., 1999; Owens et al., 2004; Rensen et al., 2007; Yoshida and Owens, 2005). Members of the conserved Hox family of transcriptional regulators known to specify positional identities during embryonic patterning through a Hox code (Kessel and Gruss, 1991; McGinnis and Krumlauf, 1992) qualify as prime candidates for determining and maintaining positional identities in the vascular system. This idea is supported by recent data demonstrating topographic Hox expression patterns with distinct boundaries in VSMCs and endothelial cells of adult blood vessels (Pruett et al., 2008); the spatial coordinates of these vascular Hox domains roughly correspond to the respective Hox domains during embryonic development (Pruett et al., 2008). These results are consistent with data obtained by gene expression profiling of cultured human fibroblasts derived from various anatomic sites indicating that topographic Hox expression signatures are retained to some degree in certain adult tissues (Chang et al., 2002; Rinn et al., 2006). Hox genes may thus be critical for regulating site-specific differentiation processes in adult tissues, including the vasculature.
As an initial step towards testing the functional significance of topographic Hox patterns in the cardiovascular system, we designed a new transgenic mouse model by using an innovative integrated Tet-regulatory system for inducing changes in vascular Hox expression. Our data show that universal induction of Hoxc11 expression in VSMCs results in region-specific vascular remodeling responses involving distinct histological and molecular changes. These results suggest that properly regulated Hox activity patterns are critical for maintaining vessel wall homeostasis in a region-specific manner. This has important implications for the development of vascular diseases that exhibit topographic patterns.
Results and Discussion
To induce changes to the distinct vascular Hoxc11 expression pattern normally restricted to the lower hindlimb vessels (Pruett et al., 2008) we used an integrated tetracycline (Tet)-regulatory system (Bäckman et al., 2004) and Transgelin (Tagln) promoter elements that drive expression preferentially in VSMCs (Li et al., 1996). Profound morphological changes in the vasculature of male doxycycline (dox) –treated TetOn(Tagln-Hoxc11) mice (n = 3) (Fig. 1F–I) compared to controls (Fig. 1B–E) were found by histopathological analysis of anatomically distinct vessel segments (external carotid artery, aortic arch, thoracic aorta, and femoral artery). Vessel wall remodeling in dox-induced mice was indicated by fragmentation of the elastic lamellae in the tunica media layer of anterior vessels including carotid artery, aortic arch, and thoracic aorta (Fig. 1F–H). In addition, intimal lesions were observed in carotid artery segments (asterisk, Fig. 1F) while medial lesions at the adventitial interface were observed in the aortic arch and thoracic aorta (black arrows, Fig. 1G,H). In contrast, the femoral artery of dox-induced mice exhibited no overt remodeling events in the vessel wall (Fig. 1I). Morphometric analysis of these vessels revealed significant differences in medial area (MA) and luminal area (LA) between the two groups with the exception of the carotid artery (Fig. 1J,K). Mean area values of dox-induced aortic arch MA and LA were lower by 35.1% and 53.7%, respectively (ANOVA, F(2,35) = 2358, P<0.0001), and dox-induced thoracic aorta MA and LA were lower by 20.3% and 12.3%, respectively (ANOVA, F(2,35) = 2030, P<0.0001); the reduction of the medial areas of these two large arteries suggests a loss of vascular smooth muscle cells (VSMCs). In contrast, the femoral artery of dox-induced mice exhibited increases in both MA and LA mean values as compared to controls of 59.0% and 55.2%, respectively, (Fig. 1J,K) [ANOVA, F(2,35) = 25.3, P<0.0001].
HOXC11-induced vessel wall restructuring.
(A) Schematic of the integrated dox-regulated transgene construct TetOn(Tagln-Hoxc11). (B–E) Cross-sections of arteries from four different anatomical locations: carotid artery, aortic arch, thoracic aorta and femoral artery (as indicated at the top of the panels) of TetOn(Tagln-Hoxc11) transgenic mice without dox treatment (controls). (F–I) Sections of arteries from dox-treated transgenic mice that match those shown above in panels B-E; white arrows in (F,G,H) indicate fragmented elastic lamellae; asterisk (F) indicates intimal lesion, black arrows (G,H) identify medial lesions; lu, lumen; scale bars: 20 µm. (J,K) Morphometric analysis of medial area (MA) and luminal area (LA) of un-induced (UI) versus induced (IN) vessel segments (carotid artery, aortic arch, thoracic aorta, femoral artery) as schematically depicted in the cartoon (panel K) and explained in the text; values are expressed as mean ±SEM, n = 9; P<0.001 in all cases.
(A) Schematic of the integrated dox-regulated transgene construct TetOn(Tagln-Hoxc11). (B–E) Cross-sections of arteries from four different anatomical locations: carotid artery, aortic arch, thoracic aorta and femoral artery (as indicated at the top of the panels) of TetOn(Tagln-Hoxc11) transgenic mice without dox treatment (controls). (F–I) Sections of arteries from dox-treated transgenic mice that match those shown above in panels B-E; white arrows in (F,G,H) indicate fragmented elastic lamellae; asterisk (F) indicates intimal lesion, black arrows (G,H) identify medial lesions; lu, lumen; scale bars: 20 µm. (J,K) Morphometric analysis of medial area (MA) and luminal area (LA) of un-induced (UI) versus induced (IN) vessel segments (carotid artery, aortic arch, thoracic aorta, femoral artery) as schematically depicted in the cartoon (panel K) and explained in the text; values are expressed as mean ±SEM, n = 9; P<0.001 in all cases.
Potential co-expression of molecular markers for vascular remodeling including MMP2, MMP9 (Raffetto and Khalil, 2008) and CASP3 (Ono et al., 2005) with HOXC11 upon TetOn(Tagln-Hoxc11) induction in the thoracic aorta and in femoral artery was examined by immunolabeling. The results indicate co-localization of HOXC11 with MMP2 and MMP9 in VSMCs (white arrows) and endothelial cells (grey arrows, Fig. 2B–D and Fig. 2J–L, respectively) of the thoracic aorta following one week of dox treatment, whereas in control sections HOXC11 expression was not detected (Fig. 2G,O). Faint signal for MMP2 was detectable in control sections where it localized to the periphery of elastic lamellae (green arrow, Fig. 2H) while signal for MMP9 was absent in the controls (Fig. 2P). Following a short three-day dox treatment, CASP3 was detectable in VSMCs adjacent to the intimal and adventitial interfaces and endothelial cells (large and small black arrows, respectively, Fig. 2Q) that was not detected in the controls (Fig. 2R); analysis of CASP3 expression was done after a three-day dox treatment as this is an early event in vascular remodeling (Spiguel et al., 2010).
MMP2/MMP9 and CASP3 expression in thoracic aorta upon TetOn(Tagln-Hoxc11) induction.
(A–D) Thoracic aorta cross section from dox-induced (1 week) TetOn(Tagln-Hoxc11) transgenic mouse imaged with differential interference contrast (DIC; panel A) showing co-expression (merge; yellow signal in panel B) of individual immunofluorescent signals for HOXC11 and MMP2 (C and D, respectively). (E–H) In cross-section of un-induced counterpart HOXC11 expression was not detected (G) and MMP2 signal was barely detectable (green arrow; panel H). (I–L) Thoracic aorta cross section from an induced transgenic mouse imaged with DIC (panel I) showing co-expression (yellow signal; panel J) of individual immunofluorescent signals for HOXC11 and MMP9 (K and L, respectively). (M–P) Thoracic aorta cross-section of un-induced counterpart indicated lack of HOXC11 and MMP9 expression. (Q,R) Immunofluorescent signals for CASP3 (red) were superimposed on DIC images of induced (Q) and un-induced thoracic aorta (R) indicating increased apoptosis in dox-induced (3 days) mouse vessel. All vessel segments were harvested and processed in parallel. Imaging was performed on an upright brightfield/fluorescence microscope (Leica DMR) equipped a SPOT RT3 camera and SPOT v4.6.1.40 imaging software. Scale bars: 20 µm.
(A–D) Thoracic aorta cross section from dox-induced (1 week) TetOn(Tagln-Hoxc11) transgenic mouse imaged with differential interference contrast (DIC; panel A) showing co-expression (merge; yellow signal in panel B) of individual immunofluorescent signals for HOXC11 and MMP2 (C and D, respectively). (E–H) In cross-section of un-induced counterpart HOXC11 expression was not detected (G) and MMP2 signal was barely detectable (green arrow; panel H). (I–L) Thoracic aorta cross section from an induced transgenic mouse imaged with DIC (panel I) showing co-expression (yellow signal; panel J) of individual immunofluorescent signals for HOXC11 and MMP9 (K and L, respectively). (M–P) Thoracic aorta cross-section of un-induced counterpart indicated lack of HOXC11 and MMP9 expression. (Q,R) Immunofluorescent signals for CASP3 (red) were superimposed on DIC images of induced (Q) and un-induced thoracic aorta (R) indicating increased apoptosis in dox-induced (3 days) mouse vessel. All vessel segments were harvested and processed in parallel. Imaging was performed on an upright brightfield/fluorescence microscope (Leica DMR) equipped a SPOT RT3 camera and SPOT v4.6.1.40 imaging software. Scale bars: 20 µm.
Expectedly, HOXC11 was detected in distal femoral arteries of both induced and non-induced mice (red signal, Fig. 3A,D), respectively, with a concomitant induction of MMP2 in induced animals (red signal, Fig. 3E) that was absent in the controls (Fig. 3B). Since we cannot discriminate between endogenous and transgene-induced HOXC11, we conclude that the MMP2 induction in dox-treated mice resulted from increased levels of HOXC11 expression (supplementary material Fig. S1). No signal for MMP9 expression was detected in either group (induced or non-induced) (Fig. 3C,F) respectively.
Changes in femoral artery of dox-induced TetOn(Tagln-Hoxc11) transgenic and Hoxc11−/− knockout mice.
(A–C) Femoral artery sections (FAS) of a non-induced transgenic mouse immunolabeled with HOXC11, MMP2 and MMP9 antibodies as indicated at the top reveal HOXC11 expression (red signal; panel A); FAS of dox-induced (3 days) transgenic mouse (D–F) show in addition to HOXC11 expression (D) induced expression of MMP2 (E) in a largely similar pattern. (G–I) In a separate experiment, FAS of wild type C57BL/6 mouse immunolabeled with HOXC11, MMP2 and MMP9 antibodies show HOXC11 expression (G) and faint MMP2 expression signals (arrows in H); (J–L) FAS of Hoxc11−/− mouse show expression of truncated HOXC11 (J) and faint MMP2 expression (arrows in I). (M,N) Movat's pentachrome-stained FAS from wild type (WT) (M) and Hoxc11−/− mice (N). (O) Morphometric analysis of medial area (MA) and luminal area (LA) of wild-type (WT) versus Hoxc11−/− FAS; values and comparisons (explained in text) are expressed as mean ±SEM, n = 9; P<0.001. Scale bars: 20 µm.
(A–C) Femoral artery sections (FAS) of a non-induced transgenic mouse immunolabeled with HOXC11, MMP2 and MMP9 antibodies as indicated at the top reveal HOXC11 expression (red signal; panel A); FAS of dox-induced (3 days) transgenic mouse (D–F) show in addition to HOXC11 expression (D) induced expression of MMP2 (E) in a largely similar pattern. (G–I) In a separate experiment, FAS of wild type C57BL/6 mouse immunolabeled with HOXC11, MMP2 and MMP9 antibodies show HOXC11 expression (G) and faint MMP2 expression signals (arrows in H); (J–L) FAS of Hoxc11−/− mouse show expression of truncated HOXC11 (J) and faint MMP2 expression (arrows in I). (M,N) Movat's pentachrome-stained FAS from wild type (WT) (M) and Hoxc11−/− mice (N). (O) Morphometric analysis of medial area (MA) and luminal area (LA) of wild-type (WT) versus Hoxc11−/− FAS; values and comparisons (explained in text) are expressed as mean ±SEM, n = 9; P<0.001. Scale bars: 20 µm.
To determine potential changes in the femoral artery of Hoxc11−/− mice that might reveal a role for Hoxc11 in vascular patterning during development, we performed a limited histopathological analysis of these mice. Morphometric measurements of medial and luminal femoral artery areas (MA and LA, respectively) from Hoxc11−/− mice and wild-type littermates (n = 3) at 6 weeks of age showed remarkable increases of 72.6% in MA and 239% in LA for Hoxc11−/− compared to control mice (Fig. 3M–O) [ANOVA, F(3,39) = 476.3, P<0.0001]. Interestingly, this vessel enlargement is accompanied by transformations of sacral (S) and caudal (C) vertebrae from posterior towards anterior identities, including S3 to S2 and C1 to S4 transformations (supplementary material Fig. S2) that may be considered classic homeotic transformations as expected from the inactivation of AbdB-type (“posterior”) Hox genes (Gehring, 1987; Lewis, 1978; Mallo et al., 2010; Wellik, 2007). This raises an intriguing question, i.e. whether the femoral artery enlargement in Hoxc11−/− mice might conceptually also be viewed as a homeotic transformation, in this case from distal vessel of smaller size towards a larger more proximal vessel; addressing this will be the focus of future studies. Although this vessel enlargement superficially resembled the enlargement observed in dox-treated TetOn(Tagln-Hoxc11) transgenic mice, where this was accompanied by the induction of robust MMP2 expression (Fig. 3E), the comparatively weak MMP2 expression detected in femoral artery VSMCs and endothelial cells of Hoxc11−/− mice (Fig. 3K) was essentially indistinguishable from wild type (Fig. 3H), and MMP9 expression was undetectable in both (Fig. 3F,L). Interestingly, the mosaic expression pattern of truncated and native HOXC11 in the femoral artery of Hoxc11−/− and wild type mice, respectively, was essentially the same (Fig. 3G,J); the epitope recognized by the anti-HOXC11 antibodies is exon 1-specific, while the targeted alteration of HOXC11 disrupts exon 2 (Wellik et al., 2002) thus allowing for detection of the truncated protein.
The presence of multiple copies of the TTTA(T/C) HOXC11 consensus binding sequence (Sur and Toftgård, 2000) within the Mmp2 and Mmp9 promoter regions (Fig. 4A) suggests potential direct regulatory interactions with HOXC11. To test this, we performed chromatin immunoprecipitation (ChIP) assays with MOVAS cells transiently transfected with a plasmid encoding a FLAG-tagged (N-terminal) version of HOXC11 (F-HOXC11); endogenous Hoxc11 expression was not detected in MOVAS cells by semi-quantitative PCR (supplementary material Fig. S3). Immunoprecipitated chromatin fragments (anti-FLAG) yielded Mmp2 and Mmp9-specific amplicons of expected sizes upon PCR amplification not observed with the control reactions (Fig. 4B). To further validate HOXC11 interaction with Mmp2 and Mmp9 promoters, we performed co-transfection assays with MOVAS cells utilizing HOXC11 expression plasmids encoding either full-length HOXC11 or a homeodomain-deleted version of HOXC11 (HOXC11Δhd) and FLAG-tagged versions of both (F-HOXC11 and F-HOXC11Δhd) along with Mmp2- and Mmp9-luciferase (Mmp2- and Mmp9-luc) reporter plasmids containing 2.7 and 1.9 kb of respective proximal promoter sequences (Fig. 4A). Cells co-transfected with vehicle plus Mmp2-luc or Mmp9-luc (controls) showed considerable basal levels of luciferase activity (Fig. 4C,D) consistent with recent reports showing MMP2 and MMP9 to be expressed in aortic ring VSMC primary cultures (Dwivedi et al., 2009; Risinger et al., 2010); in addition, Mmp9 is specifically expressed in MOVAS cells (Lau et al., 2009). Co-transfection of Mmp2-luc with HOXC11 or F-HOXC11 resulted in significant inhibition of luciferase activity, 3.80-fold and 4.66-fold, respectively (Fig. 4C) [ANOVA, F(4,29) = 280.9, P<0.0001]. Significantly reduced inhibition was found upon co-transfection with HOXC11Δhd and F-HOXC11Δhd, 2.24-fold and 1.83-fold, respectively. An analogous set of co-transfection assays with Mmp9-luciferase yielded overall very similar results although with an even greater degree of inhibition associated with co-expression with HOXC11 and F-HOXC11, 7.88-fold and 12.89-fold respectively (Fig. 4D) [ANOVA, F(4,44) = 125.5, P<0.0001]. An even greater release of inhibition was observed upon co-transfection with HOXC11Δhd and F-HOXC11Δhd, 2.87-fold and 2.23-fold, respectively (Fig. 4D), P<0.0001. These results are consistent with the non-normalized set of data for these same experiments as both show the same trends in luciferase activities (compare Fig. 4 to supplementary material Fig. S4); this is an important observation as interference with the expression of the control reporter plasmid can result in biased interpretation of the normalized data (Vesuna et al., 2005). A possible explanation for the opposing effects of HOXC11 expression on Mmp2 and Mmp9 reporter gene activity in MOVAS cells and the apparent induction of MMP2 and MMP9 expression upon HOXC11 activity in vivo is that plasmid-based reporter gene expression in cultured cells is unlikely to reflect authentic responses of the corresponding genes in their native cellular and nuclear environment.
HOXC11 interaction with Mmp2 and Mmp9 promoters.
(A) Schematic of Mmp2 and Mmp9 proximal promoter regions with the positions of HOXC11 consensus binding sequences [TTTA(T/C)] indicated by vertical bars. Location of PCR amplicons used for detecting immunoprecipitated chromatin are shown by horizontal black bars. (B) ChIP assays using MOVAS cells transfected with FLAG-tagged HOXC11 (F-HOXC11); PCR amplification of chromatin fragments precipitated with anti-FLAG antibodies (a-FLAG) yielded gene-specific amplicons for both Mmp2 and Mmp9 but not for Krt1 used as negative control; PCR reactions using chromatin precipitated with pre-immune rabbit IgG and with a-FLAG/Mock (vehicle-only) failed to produce promoter-specific amplicons in all cases. (C,D) HOXC11 inhibits the luciferase activity of reporter vectors carrying the Mmp2 and Mmp9 promoter sequences as depicted above (A); histograms of normalized luciferase activity of MOVAS cells co-transfected with Mmp2- (C) and Mmp9-luciferase (D) vectors and vectors encoding either HOXC11, HOXC11 minus the homeodomain (HOXC11ΔHD), FLAG-tagged HOXC11 (F-HOXC11) or FLAG-tagged HOXC11 minus the homeodomain (F-HOXC11ΔHD) 48 hours prior to measuring luciferase activity.
(A) Schematic of Mmp2 and Mmp9 proximal promoter regions with the positions of HOXC11 consensus binding sequences [TTTA(T/C)] indicated by vertical bars. Location of PCR amplicons used for detecting immunoprecipitated chromatin are shown by horizontal black bars. (B) ChIP assays using MOVAS cells transfected with FLAG-tagged HOXC11 (F-HOXC11); PCR amplification of chromatin fragments precipitated with anti-FLAG antibodies (a-FLAG) yielded gene-specific amplicons for both Mmp2 and Mmp9 but not for Krt1 used as negative control; PCR reactions using chromatin precipitated with pre-immune rabbit IgG and with a-FLAG/Mock (vehicle-only) failed to produce promoter-specific amplicons in all cases. (C,D) HOXC11 inhibits the luciferase activity of reporter vectors carrying the Mmp2 and Mmp9 promoter sequences as depicted above (A); histograms of normalized luciferase activity of MOVAS cells co-transfected with Mmp2- (C) and Mmp9-luciferase (D) vectors and vectors encoding either HOXC11, HOXC11 minus the homeodomain (HOXC11ΔHD), FLAG-tagged HOXC11 (F-HOXC11) or FLAG-tagged HOXC11 minus the homeodomain (F-HOXC11ΔHD) 48 hours prior to measuring luciferase activity.
While induction of TetOn(Tagln-Hoxc11) activity outside the normal Hoxc11 expression domain (Pruett et al., 2008) resulted in rather uniform HOXC11 expression in the vessel walls as judged by immunolabeling (Fig. 2), this was not the case in the femoral artery, where HOXC11 expression appeared in a mosaic pattern (Fig. 3) that resembled the endogenous pattern (Fig. 3) (Pruett et al., 2008). This is likely to reflect phenotypic heterogeneity among VSMCs and suggests regulatory mechanisms selectively suppressing TetOn(Tagln-Hoxc11) activity in certain cells. A possible explanation includes the involvement of other topographically expressed transcription factors (e.g. the AbdB-type Hoxc9, Hoxc10, Hoxd10, and Hoxa11) that are expressed in the same vessel segment as Hoxc11 (Pruett et al., 2008) but not necessarily in the same cells. In support of this idea, in silico analysis of the Tagln promoter sequences present in TetOn(Tagln-Hoxc11) revealed the presence of 13 bona fide AbdB-type HOX binding sequences (Benson et al., 1995) that could mediate this selective transgene repression.
We demonstrate that dysregulated expression of Hoxc11 in adult arteries resulted in profound vascular remodeling with distinct regionally restricted morphological and molecular changes. Ectopic expression in the large arteries (external carotids, aortic arch and thoracic aorta) was marked by fragmentation of elastic laminae, loss of VSMCs and formation of intimal lesions as reflected by the induction of MMP2, MMP9, and CASP3 activity. In contrast, induction of TetOn(Tagln-Hoxc11) activity within the endogenous vascular Hoxc11 domain, as illustrated by the analysis of the femoral artery, resulted in approximately 2-fold enlargement of this vessel but without overtly recognizable changes in vessel wall structure, and without MMP9 and CASP3 induction. This differential response to TetOn(Tagln-Hoxc11) activation supports our idea that Hox-specified positional identity is both retained and functional in the adult arterial system. Conceptually, this may be viewed as a vascular Hox code that provides the genetic basis for maintaining vessel wall homeostasis and functional diversity.
This new concept has potential clinical relevance as illustrated by data that indicate topographic patterns in the development of various vascular diseases. A good example is the localized formation of abdominal aortic aneurysms (AAA) whose formation involve genetic mechanisms that are distinct from those that underlie thoracic aortic aneurysms (Lindsay and Dietz, 2011); within this context it is of interest that AAA is associated with loss of HOXA4 expression (Lillvis et al., 2011). Furthermore, the finding of distinct topographic variations in the development of arterial occlusive disease in spite of uniform systemic risk factors (sex, cholestorol, triglyceride levels, smoking, hypertension) was thought to indicate genetic differences in the arterial bed (DeBakey and Glaeser, 2000). This idea is consistent with data that showed a clear propensity for atherosclerotic lesion progression at the left anterior descending coronary artery compared to the thoracic and abdominal aorta (Homma et al., 2008). Finally, CpG islands associated with HOXC11 were found to be hypomethylated in human atherosclerotic coronary arteries suggesting ectopic activation of this gene during atherosclerotic lesion formation (Castillo-Díaz et al., 2010); this finding is consistent with the vessel wall restructuring induced by ectopic Hoxc11 expression in mice presented here.
Materials and Methods
HOXC11 expression vectors and luciferase reporter constructs
Hoxc11 coding sequence (cds) was isolated by PCR from an E16 mouse embryo (FVB/N) cDNA library generated with SuperScript® III (Invitrogen, Carlsbad, CA); primer pair: 5′-CCGGAGGAGGCAGGAGAAGA and 5′-TCTTTCCCTCCCTCCCACCCCAAA; the subcloned cds (TOPO TA Kit, Invitrogen) was excised (EcoRI) and cloned into pCDNA3.1+ (Invitrogen) to generate pHOXC11; alternatively, blunt-ended cds was cloned into the end-filled BamHI site of a FLAG-tagged version of pCDNA3.1+ (Potter et al., 2006) to generate pF-HOXC11. Homeodomain (hd) -deleted versions of these vectors (pHOXC11Δhd and pF-HOXC11Δhd) were generated by removal of an Eco47III-XhoI fragment encoding hd residues 4–60. Mmp2 and Mmp9 promoter regions were isolated by PCR from BAC clones RP24-138B4 and RP24-320F19 (CHORI, Oakland CA), respectively, using Expand High FidelityPLUS System (Roche, Indianapolis, IN) with specific primer pairs as listed in supplementary material Table S1; forward and reverse primers included an Mlu1 and Xho site, respectively, thus facilitating cloning into pGL2-Basic containing Photinus pyralis luciferase sequences (Promega, Madison, WI) to generate pMmp2-luc and pMmp9-luc.
Transgenic and knockout mice
The Tagln promoter harbored in pSM22#43 vector (Li et al., 1996) was inserted into the end-filled XhoI site of pe2TetOnFKNF(PacI) (Bäckman et al., 2004) to generate pe2TetOn(Tagln2.7); the Hoxc11 coding sequence (cds) excised from pHOXC11 was inserted into the PacI site of pe2TetOn(Tagln2.7) to generate pTetOn(Tagln-Hoxc11). TetOn(Tagln-Hoxc11 transgenic mice were created on an inbred FVB/N strain background as described (Gordon and Ruddle, 1983). Transgene activity was induced at 6–8 weeks of age by supplementing the drinking water with 3% sucrose and 500 µg/ml of doxycycline exchanged every third day. Hoxc11−/− mice were described previously (Wellik et al., 2002).
Blood vessel dissection and histological analysis
Defined blood vessel segments of dox-treated (2 weeks) and non-treated TetOn(Tagln-Hoxc11) mice (n = 3) were dissected (carotid artery: within 1 mm anterior of the internal/external carotid branch point; aortic arch: transverse-midpoint between left carotid and innominate arterial branches; thoracic aorta: between 7th and 8th intercostal arterial branch points; femoral artery: within 1 mm anterior of the tibial artery branch point). Morphometric measurements of three randomly selected, histologically stained (Movat's pentachrome staining kit; Electron Microscopy Services, Hatfield, PA) and digitally imaged sections were performed by using ImageJ software v1.4 (http://rsb.info.nih.gov/ij/) as described (Moore and Hui, 2005).
Immunolabeling
Immunolabeling was performed as described (Pruett et al., 2008) by using chicken-anti-mouse HOXC11(Pruett et al., 2008); rabbit-anti-human/mouse MMP2 (AB19167; Millipore, Temecula, CA), rabbit-anti-rat/mouse MMP9 (AB19016; Millipore, Temecula, CA), and rabbit-anti-human/mouse CASP3 (ab13847; Abcam, Cambridge, MA) antibodies.
ChIP and co-transfection assays
Assays were performed with MOVAS cells (ATCC, Rockville, MD) by using the ChIP-IT Express Enzymatic kit (Active Motif, Carlsbad, CA) and Luciferase Assay System (Promega, Madison WI) according to manufacturer's instructions and as previously reported (Potter et al., 2006). For ChIP, anti-FLAG antibodies (Sigma, St. Louis, MO) were used and precipitated chromatin samples were amplified by PCR (35 cycles) using primer pairs specific for Mmp2, Mmp9, and Krt1 promoter regions as listed in supplementary material Table S1.
Statistical analysis
In all cases ANOVA analysis (one-way) with subsequent Student-Newman-Keul's Test post hoc analysis was used for comparisons of means between groups with statistical significance set at the P<0.05 level.
Methods used for supplementary material Fig. S1
Total RNA of mouse femoral artery and carotid artery was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA), and cDNA was generated from 200 ng of total RNA using SuperScript III RNase H reverse transcriptase with random primers (Invitrogen, Carlsbad, CA). Q-PCR reactions were performed by using RT″ PCR SYBR® Green Mastermix (Qiagen) and Hoxc11 forward and reverse primers 5′-AGGCTCCCTCTCGTCAGATTT and 5′-CTCCCGGTGCATAAGCTCG, respectively, on a BIO-RAD (Hercules, CA) MyiQ thermocycler. Mouse Gapdh forward and reverse primers: 5′-TGTTCCTACCCCCAATGTGT, and 5′-GGTCCTCAGTGTAGCCCAAG.
Acknowledgements
We gratefully acknowledge Eric Olson for providing the Tagln promoter sequences and Andreas Tomac for the integrated TetOn transgene system. We thank Donna Jacobs for help with the maintenance of the transgenic mouse colony, Mary Ann Baybo for help with co-transfection assays, and Jeremy Barth for help with the analysis of Q-PCR data. This study was supported by NIAMS grant 2AR01AR47204 to A.A., NHLBI grant 1R01HL093594 to MWM, and NHLBI training grant HJL07260 to N.D.P., as well as a grant from the National Center for Research Resources (P20RR016434) from the NIH. The authors gratefully acknowledge a partial waiver of publication charges by Biology Open.
References
Competing interests
The authors declare that there are no competing interests.
Supplementary information
Fig. S2.Hoxc11−/−vertebral alterations.Hoxc11 knockout mice exhibit alterations in vertebral patterning as revealed by alcian blue/alizarin red (A/A) skeletal staining and microcomputed tomography (MicroCT) scanning. Wild-type C57BL/6 mice have a typical vertebral pattern of C7T13L6S4Cd(t)4 (C, cervical; T, thoracic; L, lumbar; S, sacral; Cd(t), caudal with peg-like transverse process); however, Hoxc11 mutant mice (n = 8) were found to have a C7T13L6S6Cd(t)4 pattern varying in the number of sacral vertebrae present in a manner similar to that seen for Hoxc10-targeted mutant mice ( Hoxc10−/−) that display a C7T12(T13/L1)L5S5 pattern in which the fourth sacral (S4) vertebra transforms into an S3 vertebra with a concomitant transformation of the first caudal vertebra into an S4 resulting in a single additional sacral vertebra ( Hostikka et al., 2009). In the case of Hoxc11 knockout mice this transformation occurs at the level of the S3 vertebra, which transforms into an S2/S3 hybrid based on transverse process morphology; this transformation is most obvious at 49 dpn (days post natum) where the normally club-shaped S3 vertebra exhibits the broad, anvil-shaped morphology of the S2 vertebra. The S3 and S4 vertebrae appear normal while the first caudal vertebra transforms to a C1/C4 hybrid due to its position and process morphology.
Fig. S4.HOXC11 represses Mmp2 and Mmp9 reporter genes in co-transfection assays. Histograms of non-normalized luciferase activity of MOVAS cells co-transfected with Mmp2- (A) and Mmp9-luciferase (B) vectors and vectors encoding either HOXC11, HOXC11 minus the homeodomain (HOXC11ΔHD), FLAG-tagged HOXC11 (F-HOXC11) or FLAG-tagged HOXC11 minus the homeodomain (F-HOXC11ΔHD) 48 hours prior to measuring luciferase activity. For further explanations see legend to Fig. 4 in the main text.